[Sequencing of adjuvant treatment after surgery for invasive breast cancer].
The majority of patients with newly diagnosed invasive breast cancer require adjuvant treatment after surgery with radiation, chemotherapy, and hormonal treatment. This article reviews the important topic of treatment sequencing in breast cancer to optimally integrate all the adjuvant treatments.
Petit
T
T
Centre Léon-Bérard, 28, rue Laënnec, 69373 Lyon, France. tpetit@strasbourg.fnclcc.fr
Claude
L
L
Carrie
C
C
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011182:Postoperative Care; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D006728:Hormones; D013629:Tamoxifen; D004317:Doxorubicin; D003520:Cyclophosphamide; D000068878:Trastuzumab; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate